Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
11 Maio 2023 - 9:00AM
Morphic Therapeutic (NASDAQ: MORF) today announced the presentation
of new preclinical data in the MORF-057 IBD development program
that are consistent with previous findings and add new support to
mechanistic understanding of the molecule’s activity in a nonhuman
primate (NHP) model of ulcerative colitis. The poster presentation
was made at Digestive Disease Week (DDW) 2023.
“The data presented at DDW continue to refine
and reinforce our understanding of the
pharmacokinetic-pharmacodynamic relationship of α4β7 inhibition
with respect to cellular biomarkers and MORF-057’s translation to
treatment of patients. Further, these results link Morphic’s small
molecule α4β7 inhibitors with the pharmacology associated with
approved anti-integrin IBD treatments,” commented Bruce Rogers,
PhD, President of Morphic.
The study presented at DDW examines longitudinal
changes in circulating biomarkers in nonhuman primates (NHP)
infused with stepwise increasing doses of MT-105, a small-molecule,
selective α4β7 integrin inhibitor tool compound with similar
chemical properties to MORF-057.
Key findings from the NHP study included
consistency of biomarker data when compared with previous MORF-057
results and with observations from the approved monoclonal antibody
α4β7 inhibitor. α4β7 inhibition with MT-105 elicits similar
changes, including α4β7 receptor occupancy and lymphocyte subset
changes, to those seen in humans receiving α4β7-targeted monoclonal
antibodies or Morphic’s small molecule inhibitor of α4β7, MORF-057.
The tool compound also demonstrates consistency of pharmacokinetic
effect between individual animals with highly similar exposure
response curves measuring the memory T cell biomarker. Notably,
unbiased single cell RNA sequencing (scRNAseq) of pretreatment and
MT-105-treated peripheral blood mononuclear cells reveals
consistent increases in circulating plasma cells and plasmablasts
correlated with increasing exposure of MT-105. These data suggest
that α4β7 inhibition with MT-105 impacts antibody secretion related
to gut inflammation.
Poster Sa1761: Predictive
Translational Blood Biomarkers Dynamics of small molecule A4B7
inhibition in Nonhuman Primate
Authors: Jamie Wong, Dooyoung
Lee, Huidong Chen, Maloy Mangada, Bryce Harrison, Matthew G.
Bursavich, Adrian S. Ray, Bruce N. Rogers, and Blaise Lippa
Poster: DDW poster Sa176 is
available on the Investors tab of Morphic’s website.
About MorphicMorphic
Therapeutic is a biopharmaceutical company developing a portfolio
of oral integrin therapies for the treatment of serious chronic
diseases, including autoimmune, cardiovascular, and metabolic
diseases, fibrosis, and cancer. Morphic is also advancing its
pipeline and discovery activities in collaboration with Schrödinger
using its proprietary MInT technology platform which leverages the
Company’s unique understanding of integrin structure and
biology.
Forward Looking Statements
This press release contains “forward-looking”
statements within the meaning of the Securities Act of 1933, as
amended, the Securities Exchange Act of 1934, as amended, and of
the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including, but not limited to the MInT
technology platform’s ability to discover drug candidates and the
ability of MORF-057 and α4β7 inhibitors to treat IBD, including
ulcerative colitis, or related indications. Statements including
words such as “believe,” “plan,” “continue,” “expect,” “will be,”
“develop,” “signal,” “potential,” “anticipate” or “ongoing” and
statements in the future tense are forward-looking statements.
These forward-looking statements involve risks and uncertainties,
as well as assumptions, which, if they do not fully materialize or
prove incorrect, could cause our results to differ materially from
those expressed or implied by such forward-looking statements.
Forward-looking statements are subject to risks and uncertainties
that may cause Morphic’s actual activities or results to differ
significantly from those expressed in any forward-looking
statement, including risks and uncertainties disclosed in this
press release and other risks set forth in our filings with the
Securities and Exchange Commission, including Morphic’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2022
filed with the SEC on February 23, 2023 and Quarterly Report on
Form 10-Q for the quarter ended March 31, 2023 filed with the SEC
on April 25, 2023. These forward-looking statements speak only as
of the date hereof and Morphic specifically disclaims any
obligation to update these forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
ContactsMorphic TherapeuticChris
Erdmanchris.erdman@morphictx.com617.686.1718
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024